BIOAVAILABILITY ENHANCEMENT OF ACECLOFENAC NIOSOMES CONTAINING SURFATANTS AND CHOLESTEROL
The aim of study to developing and evaluating niosomal formulation of Aceclofenac in order to improve its bioavailability. Aceclofenac is the most widely used anti-inflammatory agent in the treatment of rheumatoid arthritis. Aceclofenac is a drug with narrow therapeutic index and short biological half-life. In evaluation study, the effect of the varying composition of non-ionic surfactant and cholesterol on the properties such as encapsulation efficiency, particle size, scanning electron microscopy and invitro drug release were studied. Moreover, the drug release was also modified and extended over a period of 72 hrs in all formulations. The results of invitro drug release studies showed that formulation (ANF-3) has better modified and extended over release of drug (92.19%) for 72hrs. ANF-3 emerged as the most satisfactory formulation in so far as its properties were concerned.